OBJECTIVE: Adiponectin plays an important role in pathophysiology of obesity, type 2 diabetes and cardiovascular disease. The aim of this study was to determine adiponectin concentrations in children and adolescents with type 1 diabetes in a longitudinal manner and to study the impact of age, gender, body mass index (BMI) and metabolic control. RESEARCH DESIGN AND METHODS: In this study, 88 children and adolescents with type 1 diabetes were followed longitudinally. At baseline and during follow-up, serum levels of adiponectin were measured by enzyme-linked immunoassay and correlated with clinical data, HbA1c and lipids. Healthy children (n = 259) were chosen as a control group. RESULTS: Serum adiponectin levels were significantly higher in children with type 1 diabetes compared with healthy children (13.1 vs 9.1 microg/ml at baseline, P < 0.001). Adiponectin concentrations inversely correlated with BMI s.d.s (P < 0.001). No significant difference of adiponectin levels regarding gender, diabetes duration or HbA1c was seen. Adiponectin concentrations decreased in males with type 1 diabetes during puberty (P = 0.03) while there was no significant change in females. In a subgroup of patients with new onset type 1 diabetes, adiponectin concentrations were not different from adiponectin levels in control subjects but increased during follow-up (P = 0.007). Stepwise multiple regression analysis showed that most important predictors of adiponectin levels in type 1 diabetes at the end of the study were adiponectin concentration at baseline (beta = 0.574, P < 0.001) and BMI s.d.s (beta = -0.302, P = 0.001, r2 = 0.56). CONCLUSIONS: Children and adolescents with type 1 diabetes have BMI-dependent elevated serum concentrations of adiponectin compared with healthy children.
OBJECTIVE:Adiponectin plays an important role in pathophysiology of obesity, type 2 diabetes and cardiovascular disease. The aim of this study was to determine adiponectin concentrations in children and adolescents with type 1 diabetes in a longitudinal manner and to study the impact of age, gender, body mass index (BMI) and metabolic control. RESEARCH DESIGN AND METHODS: In this study, 88 children and adolescents with type 1 diabetes were followed longitudinally. At baseline and during follow-up, serum levels of adiponectin were measured by enzyme-linked immunoassay and correlated with clinical data, HbA1c and lipids. Healthy children (n = 259) were chosen as a control group. RESULTS: Serum adiponectin levels were significantly higher in children with type 1 diabetes compared with healthy children (13.1 vs 9.1 microg/ml at baseline, P < 0.001). Adiponectin concentrations inversely correlated with BMI s.d.s (P < 0.001). No significant difference of adiponectin levels regarding gender, diabetes duration or HbA1c was seen. Adiponectin concentrations decreased in males with type 1 diabetes during puberty (P = 0.03) while there was no significant change in females. In a subgroup of patients with new onset type 1 diabetes, adiponectin concentrations were not different from adiponectin levels in control subjects but increased during follow-up (P = 0.007). Stepwise multiple regression analysis showed that most important predictors of adiponectin levels in type 1 diabetes at the end of the study were adiponectin concentration at baseline (beta = 0.574, P < 0.001) and BMI s.d.s (beta = -0.302, P = 0.001, r2 = 0.56). CONCLUSIONS:Children and adolescents with type 1 diabetes have BMI-dependent elevated serum concentrations of adiponectin compared with healthy children.
Authors: Amy S Shah; Lawrence M Dolan; Abigail Lauer; Cralen Davis; Dana Dabelea; Stephen R Daniels; Richard F Hamman; Santica Marcovina; R Paul Wadwa; Elaine M Urbina Journal: J Pediatr Endocrinol Metab Date: 2012 Impact factor: 1.634
Authors: J Brent Richards; Dawn Waterworth; Stephen O'Rahilly; Marie-France Hivert; Ruth J F Loos; John R B Perry; Toshiko Tanaka; Nicholas John Timpson; Robert K Semple; Nicole Soranzo; Kijoung Song; Nuno Rocha; Elin Grundberg; Josée Dupuis; Jose C Florez; Claudia Langenberg; Inga Prokopenko; Richa Saxena; Robert Sladek; Yurii Aulchenko; David Evans; Gerard Waeber; Jeanette Erdmann; Mary-Susan Burnett; Naveed Sattar; Joseph Devaney; Christina Willenborg; Aroon Hingorani; Jaquelin C M Witteman; Peter Vollenweider; Beate Glaser; Christian Hengstenberg; Luigi Ferrucci; David Melzer; Klaus Stark; John Deanfield; Janina Winogradow; Martina Grassl; Alistair S Hall; Josephine M Egan; John R Thompson; Sally L Ricketts; Inke R König; Wibke Reinhard; Scott Grundy; H-Erich Wichmann; Phil Barter; Robert Mahley; Y Antero Kesaniemi; Daniel J Rader; Muredach P Reilly; Stephen E Epstein; Alexandre F R Stewart; Cornelia M Van Duijn; Heribert Schunkert; Keith Burling; Panos Deloukas; Tomi Pastinen; Nilesh J Samani; Ruth McPherson; George Davey Smith; Timothy M Frayling; Nicholas J Wareham; James B Meigs; Vincent Mooser; Tim D Spector Journal: PLoS Genet Date: 2009-12-11 Impact factor: 5.917